$EQ SEC Filings

Filed On	Filing
26 Oct 2026	8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027
05 Oct 2026	8-K: Other Events On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification...
13 Aug 2026	SCHEDULE 13G
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	SCHEDULE 13G/A
05 Jun 2026	144
05 Jun 2026	Form 4: Zedelmayer Christine, Sr. Vice President and COO Received 14,584 shares by exercise or conversion ($11.4K) · Sold 14,584 shares ($42.7K)
05 Jun 2026	Form 4: Connelly Stephen, President and CSO Sold 200,000 shares ($633K) · Sold 30,975 shares ($91.1K)
04 Jun 2026	144
29 May 2026	Form 4: Tom Penny, Principal Accounting Officer Received 65,000 shares by exercise or conversion ($51K) · Sold 65,000 shares ($192K)
29 May 2026	Form 4: Demski Martha J, Director Granted 70,000 Director Stock Option (right to buy)
29 May 2026	Form 4: Pruzanski Mark, Director Granted 70,000 Director Stock Option (right to buy)
29 May 2026	Form 4: Bradbury Daniel, Director Granted 70,000 Director stock option (right to buy)
29 May 2026	Form 4: Zedelmayer Christine, Sr. Vice President and COO Received 9,821 shares by exercise or conversion ($7.56K) · Sold 9,821 shares ($26.5K) · Received 86,012 shares by exercise or conversion ($66.4K) · 1 more
29 May 2026	Form 4: McDermott Charles Douglas, Director Granted 70,000 Director Stock Option (right to buy)
29 May 2026	Form 4: Troupin Barbara, Director Granted 70,000 Director Stock Option (right to buy)
29 May 2026	8-K: Submission of Matters to a Vote of Security Holders
27 May 2026	144
15 May 2026	SCHEDULE 13G/A

Comments